Sigfox France Demonstrates the 0G Potential in Response to the Scheduled Shutdown of the Public Switched Telephone Network (PSTN)
14.5.2019 14:35:00 EEST | Business Wire | Press release
Within three years, all switched networks will have disappeared and most of them will be replaced by exchanges based on the IP protocol, with or without wires. This standardization of exchanges allows substantial gains in telecommunications infrastructures, but it generates significant costs for migrating from existing solutions based on switched networks. A lot of equipment will have to be adapted or replaced without creating added value or new services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005512/en/
The MutaKom box (Photo: Sigfox)
In order to meet this major challenge, which will impact millions of devices, Sigfox, the world's leading IoT service provider and first global 0G network operator, and J2C, a specialist in service offerings in the security market, have developed the MutaKom box, which replaces the previous wiring that linked the devices to the PSTN. The MutaKom solution offers immediate service continuity and is economically unbeatable.
The PSTN still satisfies multiple uses including: telemetry, remote reading, remote monitoring of premises, remote maintenance or remote alarms of machines, gauges, industrial automatons and alarm centres. All these equipments amount to a fleet of several million units, in France only, which will quickly need to find a simple, immediate and inexpensive alternative link.
The market for alarm control units in France only is estimated at 1.2 million (GPMSE and ADMS sources). The stakes around the termination of the PSTN are therefore crucial. With MutaKom providing an optional backup battery, alarm centres will maintain a similar energy autonomy, while increasing security against hacking or sabotage attempts. Indeed, the wireless link provided by the Sigfox 0G network is resistant to all types of jammers, and makes it impossible to cut the telephone cable to isolate the alarm from the remote monitor.
As Patrick Cason, Managing Director at Sigfox France, points out: "We are targeting a large market in Europe with millions of alarm centres and other technical equipment for which the only solution, before the arrival of the MutaKom offer, was to migrate to more expensive equipment without real added value. With this in mind, MutaKom is, in our opinion, the most competitive offer on the market”.
Christophe Sautter, Executive President of the GIP Group (Générale Industrielle de Protection), first security player in France to test the MutaKom solution: "The first tests were more than convincing. We believe that the simplicity of implementation and cost savings will be significant with a tangible impact on customer satisfaction”.
This Sigfox network application illustrates once again the potential of the 0G network to permanently or temporarily compensate for the unavailability of existing networks. The 0G standard is there to provide a minimal and functional link to serve the successive changes in telecommunications networks, which tend to become more complex in order to deliver ever more speed, while usage remains simple.
More information on MutaKom offer: www.mutakom.fr
About Sigfox
Sigfox is the initiator of the 0G network and
the world’s leading IoT (Internet of Things) service provider. Its
global network allows billions of devices to connect to the Internet, in
a straightforward way, while consuming as little energy as possible.
Sigfox unique approach to device-to-cloud communications addresses the
three greatest barriers to global IoT adoption: cost, energy consumption
and global scalability.
Today, the network is available in 60 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France, and also has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.
About J2C
J2C is a new French player, based in Montpellier,
created by specialists in the security and telecommunications market,
whose mission is to propose new service offers on the security market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005512/en/
Contact information
Press:
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
